Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (July 2018)
21 slides from Hemostemix's investor presentation, Jul 26, 2018
Slide 1: Hemostemix: Blood-derived cell therapies
HEMOSTEMIX Blood-derived cell therapies 2018
Slide 2: Forward-Looking Information
FORWARD-LOOKING INFORMATION This presentation contains forward looking statements that reflect management’s expectations regarding the future growth, results of operations, performance (both operational and financial) and business prospects and opportunities of Hemostemix Inc. (“Hemostemix” or the “
Slide 3: Hemostemix Inc. – Cell Based Therapies
HEMOSTEMIX INC. – CELL BASED THERAPIES Hemostemix Inc. (TSXV:HEM) is a public Canadian biotechnology company focused on the research, development and commercialization of blood-derived stem cell therapies. The Company has a robust IP portfolio of over 50 patents issued and pending for its technologi
Slide 4: Hemostemix – At a Glance
HEMOSTEMIX – AT A GLANCE Intellectual Property Key Partnerships • 50+ Patents issued or • Manufacturing Agreement in place pending worldwide • Licensing Agreement in place • Unique Processes • Contract Research Organization engaged • Low Risk Safety & Efficacy Expandable Platform Data Driven • Canad
Slide 5: The Importance of Stem Cell Therapy
THE IMPORTANCE OF STEM CELL THERAPY Disease Trends: CLI is a major global health problem - incidence growing with aging population CLI has limited treatment options – significant amputations and high cost to society Cardiovascular disease (“CVD”) is the number one cause of deaths in North Am
Slide 6: Technology Differentiators
TECHNOLOGY DIFFERENTIATORS Proven safety and Blood draw, safer and less Strong IP portfolio efficacy in >400 historical invasive than bone marrow of 50+ patents patients treated with ACP-01 Safe & Effective Non-surgical, enhanced cell therapy treatment for restoring circulation to damaged tissues du
Slide 7: Potential Markets
POTENTIAL MARKETS CLI - Estimated total costs up to $248B¹ in US. Cardiovascular Disease (CVD) In the United States, total costs of CVD in 2016 was $555B and is projected to be $1.1T by 2035² 1. Source: The Sage Group 2. Source: American Heart Association Report: Cardiovascular Disease: A costly Bur
Slide 8: About Critical Limb Ischemia (CLI)
ABOUT CRITICAL LIMB ISCHEMIA (CLI) Critical limb ischemia is a chronic condition and is the most severe and deadliest form of peripheral arterial disease (PAD) with limited treatment options. CLI is characterized by insufficient blood supply to lower limbs. Complications include leg and foot ulcers
Slide 9: CLI: Prevalence and the Cost of Treatment
CLI: PREVALENCE AND THE COST OF TREATMENT In 2015, almost 20 million U.S. citizens suffered from peripheral artery disease (PAD), estimated to increase to 30 million by 2030¹ Today, up to 7-8 million¹ people in the US and Europe suffer from CLI with growing prevalence in China and Japan. CLI quickly
Slide 10: ACP-01 for Critical Limb Ischemia
ACP-01 FOR CRITICAL LIMB ISCHEMIA Hope for CLI Patients Facing Amputation Extract and enrich desired cell 1 population from patient’s blood Inject cell population to form new 2 blood vessels in dying tissue Self-Donor Simple Quick Uses patient’s own cells, Cell harvest via blood draw 7 days from dra
Slide 11: CLI and the ACP-01 Benefit – The Visualization
CLI AND THE ACP-01 BENEFIT- THE VISUALIZATION 47 Days post ACP-01 Treatment Before After TSX VENTURE:HEM 11
Slide 12: Phase II Clinical Trial for CLI
PHASE II CLINICAL TRIAL FOR CLI Randomized, placebo-controlled double blind Phase II clinical trial to confirm the safety and efficacy of ACP-01 FDA and Health Canada approved protocol for continued trial Topstone Research Inc. engaged as contract research organization (“CRO”) CRO engaged Minimum 6
Slide 13: Phase II CLI Clinical Trial Milestones
PHASE II CLI CLINICAL TRIAL MILESTONES April 2018 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 H1 2019 H2 2019 H1 2020 H2 2020 Phase II CLI Trial CRO engaged D Health Canada Approval¹ US FDA Approval² D Site & Patient Recruiting⁴ First Patient Treatment³ Patient Monitoring⁴ Interim Data⁴ Study Completion
Slide 14: Study & Trial History
STUDY & TRIAL HISTORY Current Phase II Clinical Trial for CLI in progress in Canada and the USA Number of Type of Study Study Location Objective of Study Study Design Patients Study Status Subjects Pilot Safety/ To assess the feasibility and safety Thailand Open label 6 Diagnosed CLI Completed Feasi
Slide 15: Product Pipeline
PRODUCT PIPELINE Current CLI trial is a path towards other trials and commercialization Development Phase Candidate Indication Status Preclinical Clinical ACP-01 • Critical limb ischemia • Phase II clinical trial • Site enrollment and patient treatment In progress ACP-01 • Cardiac Disease • Preparin
Slide 16: Directors and Management Team
DIRECTORS AND MANAGEMENT TEAM Proven management team with extensive business, public company R&D and scientific trial experience Board of Directors Angus Jenkins David Wood Don Friesen Chairman Executive Management & Advisor Team Kyle Makofka Dr. Ravi Jain, PhD Kristin Gulka, CPA, CA President and C
Slide 17: Scientific Leadership Team
SCIENTIFIC LEADERSHIP TEAM Dr. Ravi Jain, PhD, Chief Scientific Officer • Over 16 years’ progressive scientific, research and development and management expertise • Co-founder and President of cBio Inc., a bioinformatics/software development consulting firm • cBio ranked as one of the Top-50 Fastest
Slide 18: Share Capital Overview
SHARE CAPITAL OVERVIEW Share capital structure as at June 30, 2018: Number Ex. Price Expiry Common Shares Issued and 297,698,154 outstanding Stock Options 27,407,230 $0.05-$0.10 Nov 2018-Apr 2023 Share Purchase Warrants² 116,419,292 $0.05-$0.65 Sept 2019-Dec 2020 Total Fully Diluted 445,052,940¹ Ins
Slide 19: Doctor Quotes / Patient Quotes
DOCTOR QUOTES Dr. Thomas Lindsay, Head of Division of Vascular Surgery UHN, Toronto General Hospital "Our experience with patients in this trial was very positive and I strongly support restarting the trial. New evidence from other trials continues to support stem cell therapy in PAD and the technol
Slide 20: 2018/19: Poised for Growth and Increased Shareholder Value
2018/19: POISED FOR GROWTH AND INCREASED SHAREHOLDER VALUE CLI PHASE II CLINICAL TRIAL ENROLLING SITES AND PATIENTS FULLY EXPANDABLE PLATFORM DESIGNED FOR COMMERCIALIZATION PHASE I ANGINA TRIAL COMPLETE – PLANNING PHASE II TRIAL MANUFACTURING AGREEMENT IN PLACE FOR US CERTIFIED GMP FACILITY
Slide 21: Contact Information
CONTACT INFORMATION Hemostemix Inc. Suite 1049, 150-9th Avenue SW Calgary, AB T2P 3H9 Website: www.hemostemix.com For more Information please contact: Kyle Makofka, President and CEO kmakofka@hemostemix.com 403-506-3373 TSX VENTURE:HEM 21